Cargando…

An empirically generated responder definition for rosacea treatment

OBJECTIVE: The aim of this study was to empirically generate a responder definition for the treatment of papulopustular rosacea. METHODS: A total of 8 multicenter clinical studies on patients with papulopustular facial rosacea were analyzed. All patients were treated with azelaic acid and/or compara...

Descripción completa

Detalles Bibliográficos
Autores principales: Staedtler, Gerald, Shakery, Kaweh, Endrikat, Jan, Nkulikiyinka, Richard, Gerlinger, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598547/
https://www.ncbi.nlm.nih.gov/pubmed/28932125
http://dx.doi.org/10.2147/CCID.S139352
_version_ 1783263928462082048
author Staedtler, Gerald
Shakery, Kaweh
Endrikat, Jan
Nkulikiyinka, Richard
Gerlinger, Christoph
author_facet Staedtler, Gerald
Shakery, Kaweh
Endrikat, Jan
Nkulikiyinka, Richard
Gerlinger, Christoph
author_sort Staedtler, Gerald
collection PubMed
description OBJECTIVE: The aim of this study was to empirically generate a responder definition for the treatment of papulopustular rosacea. METHODS: A total of 8 multicenter clinical studies on patients with papulopustular facial rosacea were analyzed. All patients were treated with azelaic acid and/or comparator treatments. The severity of rosacea was described by the Investigator Global Assessment (IGA) and the number of lesions. Patients with the IGA score of “clear/minimal” were considered as responders, and those staying in the range of IGA “mild to severe” as nonresponders. The respective number of lesions was determined. RESULTS: A total of 2,748 patients providing 12,410 measurements were included. After treatment, responders showed 2.23±2.48 lesions (median 2 lesions [0–3]), and nonresponders showed 13.74±10.40 lesions (median 12 lesions [6–18]). The optimal cutoff point between both groups was 5.69 lesions. CONCLUSION: The calculated cutoff point of 5.69 lesions allows discrimination of responders (5 or less remaining lesions) and nonresponders (6 or more remaining lesions) of therapeutic interventions in rosacea.
format Online
Article
Text
id pubmed-5598547
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55985472017-09-20 An empirically generated responder definition for rosacea treatment Staedtler, Gerald Shakery, Kaweh Endrikat, Jan Nkulikiyinka, Richard Gerlinger, Christoph Clin Cosmet Investig Dermatol Original Research OBJECTIVE: The aim of this study was to empirically generate a responder definition for the treatment of papulopustular rosacea. METHODS: A total of 8 multicenter clinical studies on patients with papulopustular facial rosacea were analyzed. All patients were treated with azelaic acid and/or comparator treatments. The severity of rosacea was described by the Investigator Global Assessment (IGA) and the number of lesions. Patients with the IGA score of “clear/minimal” were considered as responders, and those staying in the range of IGA “mild to severe” as nonresponders. The respective number of lesions was determined. RESULTS: A total of 2,748 patients providing 12,410 measurements were included. After treatment, responders showed 2.23±2.48 lesions (median 2 lesions [0–3]), and nonresponders showed 13.74±10.40 lesions (median 12 lesions [6–18]). The optimal cutoff point between both groups was 5.69 lesions. CONCLUSION: The calculated cutoff point of 5.69 lesions allows discrimination of responders (5 or less remaining lesions) and nonresponders (6 or more remaining lesions) of therapeutic interventions in rosacea. Dove Medical Press 2017-09-08 /pmc/articles/PMC5598547/ /pubmed/28932125 http://dx.doi.org/10.2147/CCID.S139352 Text en © 2017 Staedtler et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Staedtler, Gerald
Shakery, Kaweh
Endrikat, Jan
Nkulikiyinka, Richard
Gerlinger, Christoph
An empirically generated responder definition for rosacea treatment
title An empirically generated responder definition for rosacea treatment
title_full An empirically generated responder definition for rosacea treatment
title_fullStr An empirically generated responder definition for rosacea treatment
title_full_unstemmed An empirically generated responder definition for rosacea treatment
title_short An empirically generated responder definition for rosacea treatment
title_sort empirically generated responder definition for rosacea treatment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598547/
https://www.ncbi.nlm.nih.gov/pubmed/28932125
http://dx.doi.org/10.2147/CCID.S139352
work_keys_str_mv AT staedtlergerald anempiricallygeneratedresponderdefinitionforrosaceatreatment
AT shakerykaweh anempiricallygeneratedresponderdefinitionforrosaceatreatment
AT endrikatjan anempiricallygeneratedresponderdefinitionforrosaceatreatment
AT nkulikiyinkarichard anempiricallygeneratedresponderdefinitionforrosaceatreatment
AT gerlingerchristoph anempiricallygeneratedresponderdefinitionforrosaceatreatment
AT staedtlergerald empiricallygeneratedresponderdefinitionforrosaceatreatment
AT shakerykaweh empiricallygeneratedresponderdefinitionforrosaceatreatment
AT endrikatjan empiricallygeneratedresponderdefinitionforrosaceatreatment
AT nkulikiyinkarichard empiricallygeneratedresponderdefinitionforrosaceatreatment
AT gerlingerchristoph empiricallygeneratedresponderdefinitionforrosaceatreatment